Related Experiment Video

Updated: Jul 21, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Coronary flow reserve in young men with familial combined hyperlipidemia

O P Pitkänen1, P Nuutila, O T Raitakari

  • 1Departments of Medicine and Clinical Physiology, Turku PET Centre, Turku University, Turku, Finland.

Circulation
|April 6, 1999
PubMed

Insights

Young patients with familial combined hyperlipidemia (FCHL) show impaired coronary reactivity, particularly those with phenotype IIB. This suggests metabolic abnormalities in FCHL contribute to early heart disease risk.

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Medical Imaging

Background:

  • Familial combined hyperlipidemia (FCHL) is a common genetic disorder affecting lipoprotein metabolism.
  • FCHL is linked to 10-20% of premature coronary heart disease cases.
  • The study investigates coronary reactivity in asymptomatic FCHL patients.

Purpose of the Study:

  • To assess coronary reactivity in asymptomatic patients with familial combined hyperlipidemia.
  • To determine if functional abnormalities in coronary blood flow regulation exist in FCHL.
  • To compare coronary reactivity between FCHL patients and healthy controls.

Main Methods:

  • Positron emission tomography (PET) with 15O-labeled water was used to measure myocardial blood flow (MBF).
  • MBF was assessed at rest and during pharmacologic hyperemia induced by dipyridamole.
  • 21 male FCHL patients and 21 age-matched healthy controls were studied.

Main Results:

  • Asymptomatic FCHL patients exhibited lower MBF during maximal vasodilation compared to controls (P=0.025).
  • Coronary flow reserve (CFR) did not significantly differ between groups, but showed high variability in FCHL patients.
  • Patients with FCHL phenotype IIB demonstrated significantly lower hyperemic flow and CFR compared to phenotype IIA.

Conclusions:

  • Functional abnormalities in coronary flow regulation are present in young, asymptomatic FCHL patients, especially those with phenotype IIB.
  • These findings support the link between FCHL's metabolic abnormalities and its associated pathophysiology.
  • Phenotype IIB may be particularly associated with impaired coronary reactivity in FCHL.
Abstract

More Related Videos

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

Related Concept Videos

Blood Flow01:29

Blood Flow

Blood is pumped by the heart into the aorta, the largest artery in the body, and then into increasingly smaller arteries, arterioles, and capillaries. The velocity of blood flow decreases with increased cross-sectional blood vessel area. As blood returns to the heart through venules and veins, its velocity increases. The movement of blood is encouraged by smooth muscle in the vessel walls, the movement of skeletal muscle surrounding the vessels, and one-way valves that prevent backflow.
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...